for call. and thanks afternoon Good joining the
past highlights significant year, sharing this to with with progress forward past financial of during you from looking are this quarter. results We we made along
rapidly a deliver of circulating maybe story, the Invivyd and to people therapies viral from we who designed consequences are mission on those threats. devastating vulnerable protect to perpetually the new antibody-based For to
we Two, factors: unacceptable with The provide the of is burden on mission stay key one, keep an kind. them. represents Beginning human therapeutic is is medical to alarmingly uniquely from protect viral based three who to humanity urgently with SARS-CoV-X. and positioned and our COVID and options COVID are medicine people to three, to evolution cabinet on foundation here limited; need pace
is as have as the where amongst XX% infected. SARS-CoV-X of a many stage population the U.S. been with unchecked people broader circulating We in reached having
XXX The low with highlight vaccination of reports being of primary in while a Recent cancer. that COVID-XX continues leading families the reinfected virus the Every People heart only are lose for and rate eligible only recent remains boosters XX% is now COVID the loved death one have U.S. to compared to exceedingly cause and infected XXX rates to people the and COVID-XX, disease third series. day, evolve. behind of most booster. the received the
to that of and COVID, argue live would are trying most accepted particularly we quo not status are all society the populations. living well, While has with vulnerable
renal, Although consequences complications the COVID-XX of long-term impact numerous the complications. pulmonary, linked are neurological systems, body adults Clinic Preliminary many on Mayo healthy mild show COVID-XX and the to impact reported by remain infections gastrointestinal that immediate that unknown. including data appear long-term
disease, million continued changing facing Omicron X from risk The represent U.S. depending as and their on Additionally, remain has XX through viral alone individuals, in classified. severe increased sub-lineages. is how vulnerable evolution at are we resulting patients the threat and an populations Immunocompromised constantly death. COVID-XX between hospitalization even million of status in is
and that new drug last U.S. viral discovery of identified variants hundreds development evolution mandates months. pace. the in X fact, In keep must This been continual the have in
of market However, U.S. authorized term. to COVID-XX January for target We as no treatment opportunity are the or this open the near XXXX, consider for longer of there Invivyd antibodies monoclonal an prevention in any
$X.X billion the in For all represented approximately with quarter U.S. approved full in reference, authorized revenue. antibodies last globally, the and/or
populations protection this generated see and antiviral ongoing to, for growing revenue of not medication which will major treatment have are outside because category we approaches almost in COVID-XX as in treatment require the antibodies options. many and from and by XXXX. have referred many $X Monoclonal there with although we served Importantly, who been vaccination billion benefited populations these alone
are of engineered the the to to believe keep antibodies candidates news no of pace an to for or antibody respond uniquely a COVID-XX is While viral burden bad is, available we this treatment having high there generated for Invivyd multiple monoclonal news and next-generation positioned ongoing pipeline disease, designed with evolution. prevention need, good
of broadly members the pipeline across antibodies coronavirus neutralizing be support effective are Our prolonged to engineered family multiple their utilities. assets to
VYD-XXX, much we month, VYD-XXX development. the this components clinic combination mAb possible elected products is Earlier one Invivyd The chose combination to NVDXXX into a in NVDXXX, development to patients candidate the a our announced prioritize VYD-XXX of clinical SARS-CoV-X. strategy we that the will advance needed as as instead option pipeline plans advance provide of capital-efficient next in way. therapeutic candidate of previously to because of quickly company with enable for this us to monotherapy a believe
new combination candidate expedited may to develop take variants. Invivyd which the staggered Importantly, allow advantage time multiple to in new selected to a pathways, we prior regulatory of data drug had SARS-CoV-X antibodies potential emergence from of
clinical attractive we mechanism by the multiple established a a for see Spike candidate risk. reasons. antibodies, We reduces highly with targets feel well-understood advancement profile several safety VYD-XXX clinical SARS-CoV-X, protein a FDA-approved of as VYD-XXX for which
engineered results called version meaningful is adintrevimab X monoclonal demonstrated primary first large which our an endpoints antibody clinically of Phase its product three and global across VYD-XXX Additionally, trials.
of support has adintrevimab data the VYD-XXX. strong to Our package development potential accelerated from
Importantly, circulating that that the against products in authorized those the to currently previously variants showed led in has multiple the activity obsolescence including VYD-XXX concern, told been U.S. of neutralizing from standardized of since in-vitro assays, market.
in a pivotal to rapidly and plan the QX to support initiating X trial could positive regulatory of globally. filings we trials continue We data, X Phase XXXX assuming clinical initiate Phase Phase anticipate X that
VYD-XXX. developments several momentum of COVID external been positive have treatments, development that faster for Recently, indicate there including next-generation
White and monoclonal see of health to COVID-XX the are decision antibodies the public this impact like the end impacting asked VYD-XXX. and development House’s authorization We emergency development do our this We not the how about for strategy. could emergency-use FDA’s often COVID
the tests the for May will after continue may issue criteria. health for Soon treatments confirmed affected EUAs on FDA that EUAs and products vaccines, administration public the that that end existing and meet XX, emergency it will Biden announced that confirms the required not and be to new
industry support the Additionally, monoclonal development for antibody alternative will of efficient critical hopeful to this be regulatory that strategies therapies the unmet need. novel utilized remains
viral we evolve further our evolution SARS-CoV-X. potential need discovering, proprietary perpetually platform monoclonal add discovery our critical to and pipeline. While assets continue the threats, we Leveraging therapeutic neutralize their COVID-XX, approach, dictates options also to VYD-XXX’s to and evaluating antibodies monitoring that for ability engineering optimistic for for serve are are continued about new our to we emerging viral
probability on to COVID-XX VYD-XXX, commercial with pipeline the we our meaningful to again is of addition other results message other at medical not am have time authorization larger, any opportunity. offers COVID, are the mechanistic technology. a this that discovery We clinical a of preclinical our faster to The well I given Outside biotech opportunity believe and candidates of capitalize has remains our proprietary we a is in positioned time virus. understanding opportunity path and In higher clear. There of and aware persistent three stage. large in
now turn Officer, and Schmidt, will it discovery Chief recent pipeline review to Pete our activities. Medical our I to and ongoing development progress over
